Collectively, the current findings suggest that RAS inhibitors, some of which possess inverse agonist properties, can concomitantly mitigate the effect of increased renal Ang II and oxLDL levels on the development of CKD in patients with hypertension and dyslipidemia, although direct evidence in clinical studies to support this remains to be elucidated. Here, AGT is linked to chronic kidney disease.